Paper · 39160299
A synthetic cytotoxic T cell platform for rapidly prototyping TCR function.
Sharma G and 6 others. NPJ Precis Oncol, 2024. Cited by 3 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. A synthetic cytotoxic T cell platform for rapidly prototyping TCR function. Papers, record 39160299. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39160299
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| I2C2020 | Michael Smith Foundation for Health Research (MSFHR) | PubMed | PubMed | ||
| I2C2021 | Michael Smith Foundation for Health Research (MSFHR) | PubMed | PubMed | ||
| R21 CA226321 | NCI NIH HHS | United States | R21CA226321 | PubMed and NIH | NIH RePORTER |
| PIF005 | Genome British Columbia | PubMed | PubMed | ||
| 1R21CA226321-01 | U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) | R21CA226321 | PubMed and NIH | NIH RePORTER |
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Update of | 38,045,272 |
Source PubMed
References64
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22,484,809 | Unbiased identification of target antigens of CD8+ T cells with combinatorial libraries coding for short peptides. | Nat Med | 2012 | https://conductscience.org/library/papers/22484809 | PubMed |
| 2 | 32,816,891 | Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. | Clin Cancer Res | 2020 | https://conductscience.org/library/papers/32816891 | PubMed |
| 3 | 15,057,788 | Jurkat T cells and development of the T-cell receptor signalling paradigm. | Nat Rev Immunol | 2004 | https://conductscience.org/library/papers/15057788 | PubMed |
| 4 | 27,959,684 | T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27959684 | PubMed |
| 5 | 22,044,041 | Structural and biophysical determinants of αβ T-cell antigen recognition. | Immunology | 2012 | https://conductscience.org/library/papers/22044041 | PubMed |
| 6 | 24,323,902 | Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. | Clin Cancer Res | 2014 | https://conductscience.org/library/papers/24323902 | PubMed |
| 7 | 29,944,754 | iReceptor: A platform for querying and analyzing antibody/B-cell and T-cell receptor repertoire data across federated repositories. | Immunol Rev | 2018 | https://conductscience.org/library/papers/29944754 | PubMed |
| 8 | 30,190,323 | Natural killer cells induce distinct modes of cancer cell death: Discrimination, quantification, and modulation of apoptosis, necrosis, and mixed forms. | J Biol Chem | 2018 | https://conductscience.org/library/papers/30190323 | PubMed |
| 9 | 32,226,429 | Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations. | Front Immunol | 2020 | https://conductscience.org/library/papers/32226429 | PubMed |
| 10 | 36,589,698 | A library of cancer testis specific T cell receptors for T cell receptor gene therapy. | Mol Ther Oncolytics | 2023 | https://conductscience.org/library/papers/36589698 | PubMed |
1 to 10 of 64
See all 64 referencesCited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41,562,097 | Comprehensive self-antigen screening to assess cross-reactivity in promiscuous T-cell receptors. | Front Immunol | 2025 | https://conductscience.org/library/papers/41562097 | PubMed |
| 40,481,101 | RAN potentiates nuclear export of phosphorylated AMPK, reshaping lipid metabolism and impairing immune efficacy in lung adenocarcinoma. | NPJ Precis Oncol | 2025 | https://conductscience.org/library/papers/40481101 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| HLA-A | 3,105 | PubTator's text mining | https://conductscience.org/library/genes/3105 | NCBI Gene |
| HLA-C | 3,107 | PubTator's text mining | https://conductscience.org/library/genes/3107 | NCBI Gene |
| TRBV20OR9-2 | 6,962 | PubTator's text mining | https://conductscience.org/library/genes/6962 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39160299
GET https://conductscience.org/api/papers/v1/39160299/references?page=2